Scientific Overview

The biology and evolution of retroviruses and eukaryotic cells is very closely linked. In general, our research seeks to define how the replication of retroviruses is influenced by host gene products, with an emphasis on human and primate immunodeficiency viruses. We work in a variety of areas, but the two major themes are: (1) the identification and characterization of host-cell factors and pathways that are mimicked, manipulated and/or exploited by retroviruses and (2) identifying and understanding the mechanistic basis of host functions that have evolved specifically to provide a defense against retrovirus infection.

How the virion components Gag, Pol, Env, and RNA are transported, assembled and released from cells as infectious particles is one major focus of our efforts. The precise role of host and viral proteins in these processes has been one of the most challenging areas in retrovirology, but is gradually becoming understood. For example, we and others have shown that essentially all retroviruses, and many other enveloped viruses specifically recruit class E VPS proteins and ubiquitin ligases that normally mediate the sorting of cellular cargo at the limiting membrane of endosomes and the budding of vesicles into the endosomal lumen. Indeed, viral proteins appear able to simply redirect required cellular machinery to a different location in the cell in order to facilitate the formation of an enveloped virus particle. Other problems that we are investigating include defining how retroviral proteins select the locations within the cell at which they are assembled - in particular how this is affected by the cytoskeleton, vesicular transport pathways and the intrinsic membrane binding and multimerizing properties of Gag proteins.

Our second major area of interest is "intrinsic immunity." Throughout their evolution, most eukaryotic organisms have frequently been colononized by retrovirus. Indeed, our own genome contains a fossil record of vast numbers of now extinct retroviruses that replicated in the ancestors of modern humans, stretching back over millions of years. Because this historical barrage of retroviral infections, evolution has equipped mammals with several gene products whose primary function is to prevent or attenuate retrovirus replication. We work on several types of inhibitors that attenuate retrovirus replication: one class (exemplified by Fv1 and TRIM5) blocks infection by targeting incoming retrovirus capsids, a second comprises cytidine deaminases (eg. APOBEC3G) that induce lethal hypermutation of retroviral genomes, while a third (as yet poorly understood) activity appears to prevent the release of retroviruses from infected cells. We are also working to discover new types of natural antiretroviral defenses. Understanding how these defenses work, how ancient retroviruses may have been extinguished by them and how some retroviruses have acquired new functions that confer resistance to natural defenses could provide new opportunities to develop improved animal models of AIDS, as well as new therapies.

We work on the molecular and cellular biology of the retrovirus replication cycle. Retroviruses are molecular parasites, and one aspect of our work is to try to understand how retroviruses like HIV mimick, manipulate and exploit components of the cells they infect in order to facilitate their own replication. A particular focus is to determine how the viral components are assembled during the construction of new virus particles, and the role of viral and host proteins in this process. Another major goal is to understand the workings and evolution of natural defense mechanisms that many cells have developed to try to prevent retrovirus replication. These natural defenses interfere with several steps in retrovirus life cycle, and understanding natural variation in them, the mechanism by which they work and how retroviruses acquire resistance to them could enable completely new therapeutic strategies and the development of better animal models of human AIDS.

PAUL D. BIENIASZ, PH.D.

HHMI Investigator, Aaron Diamond Associate Professor,
Head, Laboratory of Retrovirology, The Rockefeller University

TELEPHONE: (212) 448 5070
TELEFAX: (212) 725 1126

E-MAIL: pbienias@adarc.org

ADDRESS:

Aaron Diamond AIDS Research Center 455 First Avenue New York, NY 10016

EDUCATION

1986-1990	The University of Bath, UK. B.Sc. (honors) in Biochemistry.
1992-1996	Imperial College of Science, Technology and Medicine, University of London, UK. Ph.D. in Virology
1996-1999	1996-1999 Duke University Durham, NC. Postdoc

PREVIOUS POSITIONS HELD

1990-1996	Research Assistant, Imperial College, University of London.
1992-1996	Ph.D. Candidate, Imperial College, University of London.
1996-1999	Postdoctoral Associate, Howard Hughes Medical Institute, Duke University.
1999-2003	Assistant Professor, The Rockefeller University.
2003-2004	Aaron Diamond Associate Professor, The Rockefeller University.

CURRENT POSITIONS HELD

1999-Present	Staff Investigator, Aaron Diamond AIDS Research Center.
2004-Present	Associate Professor and Head of Laboratory, The Rockefeller University.

HONORS

2003	Elizabeth Glaser Scientist Award
2003	GlaxoSmithKline Drug development and Research Award
2004	Hockaday Lecture, University College London

OTHER PROFESSIONAL ACTIVITIES AND ASSIGNMENTS

Organizer
Cold Spring Harbor Meeting on Retroviruses, 2005

Committee and grant review assignments
Member, National Institutes of Health AMCB Study Section: 2004-present
Ad hoc member, AmFAR Scientific Advisory Committee, 2003
Ad hoc member, NHLBI Special Review Panel, 2004
Ad hoc reviewer, The Campbell Foundation.

Editorial boards and journal review assignments
Member, Editorial board, Journal of Virology, 2003 – present
Member, Editorial board, Journal of Acquired Immune Deficiency Syndromes, 2004 – present
Member, Editorial board, Virology, 2004-present
Ad hoc reviewer: AIDS Research and Human Retroviruses, Current HIV Research, Drug
Discovery Today, Journal of Acquired Immune Deficiency Syndromes, Journal of Cell Biology,
Journal of Experimental Medicine, Journal of General Virology, Journal of Virology, Molecular
and Cellular Biology, Nature Medicine, Nature Immunology, Proceedings of the National
Academy Sciences, Virology, Trends in Pharmacological Sciences.

Teaching
The Rockefeller University; Contibutor to graduate Cell Biology, Virology and HIV courses,
2001/2. Co-organizer, Virology course, 2003, 2005. Columbia University; Guest lecturer,
Virology course, 2001. Harvard University; Guest lecturer, Virology course, 2004.

INVITED CONFERENCE/SYMPOSIUM PRESENTATIONS:
8th Conference on Retroviruses and Opportunistic Infections, February, 2001
7th World Congress on Advances in Oncology/5th International Symposium on Molecular Medicine, October, 2002
10th Conference on Retroviruses and Opportunistic Infections, February, 2003
Duke University Mini-symposium on pathogenic human viruses, April, 2003
NYU CFAR symposium ‘Exploring the cell with HIV’ May, 2003
West Coast Retrovirus meeting, October, 2003
NIH VRC symposium on Viral Hemorrhagic Fevers, October, 2003
4th DRP Symposium on Antiviral Drug Resistance, December, 2003
Palm Springs symposium on Pathogenesis of HIV Disease, March, 2004
Keystone Symposium on Mechanisms of HIV Pathogenesis, April, 2004
The Retrovirus Assembly Meeting (RAM2004) October, 2004
American Society For Microbiology conference on Viral immune evasion, March, 2005
Gordon Research Conference, Viruses and Cells (discussion leader) May, 2005

PUBLICATIONS

• Katseni VL, Gilroy CB, Ryait BK, Ariyoshi K, Bieniasz PD, Weber JN, Taylor-Robinson D. 1993. Mycoplasma fermentans in individuals seropositive and seronegative for HIV-1. Lancet 341:271-3.
• McClure MO, Bieniasz PD, Weber JN, Tedder RS, O'Shea S, Banatvala JE, Tudor-Williams G, Simmonds P, Holmes EC. 1995. HIV clearance in an infant? Nature 375:637-8.
• Bieniasz PD, Weiss RA, McClure MO. 1995. Cell cycle dependence of foamy retrovirus infection. J Virol. 69:7295-9.
• Bieniasz PD, Rethwilm A, Pitman R, Daniel MD, Chrystie I, McClure MO. 1995. A comparative study of higher primate foamy viruses, including a new virus from a gorilla. Virology 207:217-28.
• Bieniasz PD, Fridell RA, Anthony K, Cullen BR. 1997. Murine CXCR-4 is a functional coreceptor for T-cell-tropic and dual-tropic strains of human immunodeficiency virus type 1. J Virol. 71:7097-100.
• Bieniasz PD, Fridell RA, Aramori I, Ferguson SS, Caron MG, Cullen BR.1997. HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J.16:2599-609.
• Bieniasz PD, Erlwein O, Aguzzi A, Rethwilm A, McClure MO. 1997. Gene transfer using replication-defective human foamy virus vectors. Virology. 235:65-72.
• Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. 1998. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J. 17:7056-65.
• Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. 1999. Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism. Mol Cell Biol. 19:4592-9.
• Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. 1999. Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Proc Natl Acad Sci USA. 96:7791-6.
• Bieniasz PD, Grdina TA,Bogerd HP,Cullen BR.1999.Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclin T complexes.J Virol. 73:5777-86.
• Bieniasz PD, Cullen BR. 2000. Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J Virol. 74:9868-77.
• Martin-Serrano J, Zang T, Bieniasz PD. 2001. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med. 7:1313-9.
• Martin-Serrano J, Li K, Bieniasz PD. 2002. Cyclin T1 expression is mediated by a complex and constitutively active promoter and does not limit human immunodeficiency virus type 1 Tat function in unstimulated primary lymphocytes. J Virol. 76:208-19.
• Zhang YJ, Hatziioannou T, Zang T, Braaten D, Luban J, Goff SP, Bieniasz PD. 2002. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol. 76:6332-43.
• Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG, Bieniasz PD. 2002. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci USA. 99:11914-9.
• Hatziioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ. 2003. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22:385-94.
• Martin-Serrano J, Zang T, Bieniasz PD. 2003. Role of ESCRT-I in retroviral budding. J Virol. 77:4794-804.
• Bieniasz PD. 2003. Restriction factors:a defense against retroviral infection. Trends Microbiol. 11:286-91.
• Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD. 2003. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med. 9:1138-43. [view]
• Martin-Serrano J, Yarovoy A, Perez-Caballero D, Bieniasz PD. 2003. Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. Proc Natl Acad Sci USA. 100:12414-9.
• Martin-Serrano J, Bieniasz PD. 2003. A bipartite late-budding domain in human immunodeficiency virus type 1. J Virol. 77:12373-7.
• Hatziioannou T, Cowan S, Bieniasz PD. 2004. Capsid-dependent and -independent postentry restriction of primate lentivirus tropism in rodent cells. J Virol. 78:1006-11..
• Martin-Serrano J, Perez-Caballero D, Bieniasz PD. 2004. Context dependent effects of L-domains and ubiquitination on viral budding. J Virol. 78:5554-63.
• Hatziioannou T, Cowan S, von Schwedler UK, Sundquist WI, Bieniasz PD. 2004. Species-specific tropism determinants in HIV-1 capsid. J Virol. 78:6005-12.
• Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD. 2004. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci USA. 101:10774-9.
• Perez-Caballero D, Hatziioannou T, Martin-Serrano J, Bieniasz PD. 2004. Human immunodeficiency virus type 1 matrix inhibits and confers cooperativity on gag precursor-membrane interactions. J Virol. 78:9560-3.
• Bieniasz PD. 2004. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5:1109-15.
• Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD. 2004. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol. 78:12058-61.
• Hatziioannou T, Perez-Caballero D, Cowan S and Bieniasz PD. 2005. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol. 79:176-183.
• Martin-Serrano J, Eastman SW, Chung W, Bieniasz PD. 2005. HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway. J Cell Biol. 168:89-101.
• Eastman SW, Martin-Serrano J, Chung W, Zang T, Bieniasz PD. 2005. Identification of human VPS37C, a component of endosomal sorting complex required for transport-I important for viral budding. J Biol Chem. 280:628-636. (PMID: 15509564).
• Patton GS, Morris SA, Chung W, Bieniasz PD and McClure MO. 2005. Identification of domains in gag important for prototypic foamy virus egress. J Virol.79:6392-6399.
• Perez-Caballero D, Hatziioannou T, Yang A, Cowan S and Bieniasz PD. 2005. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol. 79:8969-8978. (PMID: 15994791).
• Simon V, Zennou V, Murray D, Huang Y, Ho DD and Bieniasz PD. 2005. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1:e6. (PMID: 16201018).
• Perez-Caballero D, Hatziioannou T, Zhang F, Cowan S and Bieniasz PD. 2005. Restriction of Human Immunodeficiency Virus Type 1 by TRIM-CypA Occurs with Rapid Kinetics and Independently of Cytoplasmic Bodies, Ubiquitin, and Proteasome Activity. J Virol. 79:15567-15572. [
• Hatziioannou T, Martin-Serrano J, Zang T and Bieniasz PD. 2005. Matrix-induced inhibition of membrane binding contributes to human immunodeficiency virus type 1 particle assembly defects in murine cells. J Virol. 79:15586-15589.
• Bieniasz PD. 2006. Late budding domains and host proteins in enveloped virus release. Virology 344:55-63.
• Neil SJ, Eastman SW, Jouvenet N and Bieniasz PD. 2006. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog. 2:e39. (PMID: 16699598).
• Lloyd AG, Tateishi S, Bieniasz PD, Muesing MA, Yamaizumi M and Mulder LC. 2006. Effect of DNA repair protein Rad18 on viral infection. PLoS Pathog. 2:e40.
• Zennou V and Bieniasz PD. 2006. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology 349:31-40.
• Zhang F, Hatziioannou T, Perez-Caballero D, Derse D and Bieniasz PD. 2006. Antiretroviral potential of human tripartite motif-5 and related proteins. Virology 353:396-409.
• Hatziioannou T, Princiotta M, Piatak M Jr, Yuan F, Zhang F, Lifson JD, Bieniasz PD. 2006. Generation of simian-tropic HIV-1 by restriction factor evasion. Science Oct 6;314:95.
• Jouvenet N, Neil SJ, Bess C, Johnson MC, Virgen CA, Simon SM, Bieniasz PD. 2006. Plasma Membrane Is the Site of Productive HIV-1 Particle Assembly. PLoS Biol. 4(12):e435.
• Doehle BP, Bogerd HP, Wiegand HL, Jouvenet N, Bieniasz PD, Hunter E, Cullen BR. 2006. The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles. J Virol. 80:12102-8.
• Lee YN, Bieniasz, PD. 2007. Reconstitution of an infectious Human endogenous retrovirus. PLoS Pathog. 3:e10.
• Bieniasz PD. 2007. An intrinsic host defense against HIV-1 integration? J Clin Invest. 117:302-4.
• Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature. 446:801-5.
• Ambrose Z, Kewalramani VN, Bieniasz PD, Hatziioannou T. 2007. HIV/AIDS: in search of an animal model. Trends Biotechnol. 25:333-7.
• Neil SJD, Sandrine VS, Sundquist WI, Bieniasz PD. 2007. An Interferon-alpha induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host and Microbe. 2:193-203.
• Zhadina M, McClure MO, Johnson MC, Bieniasz PD. 2007. Ubiquitin-dependent virus particle budding without viral protein ubiquitination. Proc Natl Acad Sci USA.104: 20031-6.
• Neil, S, Zang, T, and Bieniasz, PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature.451:425-30.
• Virgen, CA, Kratovac, Z, Bieniasz, PD* and Hatziioannou, T*. 2008. Independent generation of chimeric TRIM5-Cyclophilin proteins in two primate species. Proc Natl Acad Sci. 105:3563-8.
• Zhang, F, Perez-Caballero, D, Hatziioannou, T* and Bieniasz PD*. 2008. No effect of endogenous TRIM 5 alpha on HIV-1 production. Nat Med.14:235-6.
• Kratovac Z, Virgen CA, Bibollet-Ruche F, Hahn BH, Bieniasz PD, Hatziioannou T. 2008. Primate lentivirus capsid sensitivity to TRIM5 protein. J Virol. in press
• Ho DD, Bieniasz PD. 2008. HIV-1 at 25. Cell. 133:561-5.
• Jouvenet N, Bieniasz PD, Simon SM. 2008. Imaging the biogenesis of individual HIV-1 virions in live cells. Nature. 454(7201):236-40.
• Lee YN, Malim MH, Bieniasz PD. 2008. Hypermutation of an ancient human retrovirus by APOBEC3G. J Virol. 2008 Sep;82(17):8762-70.
• Perez-Caballero D, Soll SJ, Bieniasz PD. 2008. Evidence for restriction of ancient primate gammaretroviruses by APOBEC3 but not TRIM5alpha proteins. PLoS Pathog. 2008 Oct;4(10):e1000181.
• Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, McNatt M, Hatziioannou T, Bieniasz PD. 2009. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol. 83(4):1837-44.
• McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, Johnson WE, Neil SJ, Bieniasz PD. 2009. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 5(2):e1000300.
• Hatziioannou T, Ambrose Z, Chung NP, Piatak M Jr, Yuan F, Trubey CM, Coalter V, Kiser R, Schneider D, Smedley J, Pung R, Gathuka M, Estes JD, Veazey RS, KewalRamani VN, Lifson JD, Bieniasz PD. 2009. A macaque model of HIV-1 infection. Proc Natl Acad Sci. 106(11):4425-9.
• Brady T, Lee YN, Ronen K, Malani N, Berry CC, Bieniasz PD, Bushman FD. 2009. Integration target site selection by a resurrected human endogenous retrovirus. Genes Dev. 23(5):633-42.
• Eastman SW, Yassaee M, Bieniasz PD. 2009. A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover. J Cell Biol. 184(6):881-94.
• Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T. 2009. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe. 6(1):54-67.
• Bieniasz PD. 2009. The cell biology of HIV-1 virion genesis. 5(6):550-8. Review.
• Neil S, Bieniasz P. 2009. Human immunodeficiency virus, restriction factors, and interferon. 29(9):569-80. Review.
• Jouvenet N, Simon SM, Bieniasz PD. 2009. Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. Proc Natl Acad Sci U S A. 106(45):19114-9.
• Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell. 2009 Oct 30;139(3):499-511.
• Sauter D, Schindler M, Specht A, Landford WN, Münch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn GH, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatziioannou, T, Kirchhoff F. 2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe. 6(5):409-21.

* co-corresponding authors

• Martin-Serrano J, Zang T, Bieniasz PD. 2001. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med. 7:1313-9. [view]
• Martin-Serrano J, Li K, Bieniasz PD. 2002. Cyclin T1 expression is mediated by a complex and constitutively active promoter and does not limit human immunodeficiency virus type 1 Tat function in unstimulated primary lymphocytes. J Virol. 76:208-19. [view]
• Zhang YJ, Hatziioannou T, Zang T, Braaten D, Luban J, Goff SP, Bieniasz PD. 2002. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol. 76:6332-43. [view]
• Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG, Bieniasz PD. 2002. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci USA. 99:11914-9. [view]
• Hatziioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ. 2003. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22:385-94. [view]
• Martin-Serrano J, Zang T, Bieniasz PD. 2003. Role of ESCRT-I in retroviral budding. J Virol. 77:4794-804. [view]
• Bieniasz PD. 2003. Restriction factors:a defense against retroviral infection. Trends Microbiol. 11:286-91. [view]
• Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD. 2003. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med. 9:1138-43. [view]
• Martin-Serrano J, Yarovoy A, Perez-Caballero D, Bieniasz PD. 2003. Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. Proc Natl Acad Sci USA. 100:12414-9. [view]
• Martin-Serrano J, Bieniasz PD. 2003. A bipartite late-budding domain in human immunodeficiency virus type 1. J Virol. 77:12373-7. [view]
• 1Hatziioannou T, Cowan S, Bieniasz PD. 2004. Capsid-dependent and -independent postentry restriction of primate lentivirus tropism in rodent cells. J Virol. 78:1006-11.. [view]
• Martin-Serrano J, Perez-Caballero D, Bieniasz PD. 2004. Context dependent effects of L-domains and ubiquitination on viral budding. J Virol. 78:5554-63. [view]
• Hatziioannou T, Cowan S, von Schwedler UK, Sundquist WI, Bieniasz PD. 2004. Species-specific tropism determinants in HIV-1 capsid. J Virol. 78:6005-12. [view]
• Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD. 2004. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci USA. 101:10774-9. [view]
• Perez-Caballero D, Hatziioannou T, Martin-Serrano J, Bieniasz PD. 2004. Human immunodeficiency virus type 1 matrix inhibits and confers cooperativity on gag precursor-membrane interactions. J Virol. 78:9560-3. [view]
• Bieniasz PD. 2004. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5:1109-15. [view]
• Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD. 2004. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol. 78:12058-61. [view]
• Hatziioannou T, Perez-Caballero D, Cowan S and Bieniasz PD. 2005. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol. 79:176-183. [view]
• Martin-Serrano J, Eastman SW, Chung W, Bieniasz PD. 2005. HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway. J Cell Biol. 168:89-101. [view]
• Eastman SW, Martin-Serrano J, Chung W, Zang T, Bieniasz PD. 2005. Identification of human VPS37C, a component of endosomal sorting complex required for transport-I important for viral budding. J Biol Chem. 280:628-636. (PMID: 15509564). [view]
• Patton GS, Morris SA, Chung W, Bieniasz PD and McClure MO. 2005. Identification of domains in gag important for prototypic foamy virus egress. J Virol.79:6392-6399. [view]
• Perez-Caballero D, Hatziioannou T, Yang A, Cowan S and Bieniasz PD. 2005. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol. 79:8969-8978. (PMID: 15994791). [view]
• Simon V, Zennou V, Murray D, Huang Y, Ho DD and Bieniasz PD. 2005. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1:e6. (PMID: 16201018). [view]
• Perez-Caballero D, Hatziioannou T, Zhang F, Cowan S and Bieniasz PD. 2005. Restriction of Human Immunodeficiency Virus Type 1 by TRIM-CypA Occurs with Rapid Kinetics and Independently of Cytoplasmic Bodies, Ubiquitin, and Proteasome Activity. J Virol. 79:15567-15572. [view]
• Hatziioannou T, Martin-Serrano J, Zang T and Bieniasz PD. 2005. Matrix-induced inhibition of membrane binding contributes to human immunodeficiency virus type 1 particle assembly defects in murine cells. J Virol. 79:15586-15589. [view]
• Bieniasz PD. 2006. Late budding domains and host proteins in enveloped virus release. Virology 344:55-63. [view]
• Zennou V and Bieniasz PD. 2006. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology 349:31-40. [view]
• Neil SJ, Eastman SW, Jouvenet N, Bieniasz PD. 2006. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog. 2006 May;2(5):e39 [view]
• Lloyd AG, Tateishi S, Bieniasz PD, Muesing MA, Yamaizumi M, Mulder LC. 2006. Effect of DNA repair protein Rad18 on viral infection. PLoS Pathog. 2(5):e40. [view]
• Zhang F, Hatziioannou T, Perez-Caballero D, Derse D, Bieniasz PD. 2006. Antiretroviral potential of human tripartite motif-5 and related proteins. Virology. 30;353(2):396-409. [view]
• Hatziioannou T, Princiotta M, Piatak M Jr, Yuan F, Zhang F, Lifson JD, Bieniasz PD. 2006. Generation of simian-tropic HIV-1 by restriction factor evasion. Science. 314(5796):95. [view]
• Jouvenet N, Neil SJ, Bess C, Johnson MC, Virgen CA, Simon SM, Bieniasz PD. 2006. Plasma membrane is the site of productive HIV-1 particle assembly. PLoS Biol. 4(12):e435. [view]
• Lee YN, Bieniasz PD. 2007. Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog. 3(1):e10. [view]
• Bieniasz PD. 2007. An intrinsic host defense against HIV-1 integration? J Clin Invest. 117(2):302-4. [view]
• Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature. 2007 Apr 12;446(7137):1 p following 805. [view]
• Ambrose Z, KewalRamani VN, Bieniasz PD, Hatziioannou T. 2007. HIV/AIDS: in search of an animal model. Trends Biotechnol. 25(8):333-7. [view]
• Neil SJ, Sandrin V, Sundquist WI, Bieniasz PD. 2007. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe. 2007 Sep 13;2(3):193-203. [view]
• Zhadina M, McClure MO, Johnson MC, Bieniasz PD. 2007. Ubiquitin-dependent virus particle budding without viral protein ubiquitination. Proc Natl Acad Sci. 104(50):20031-6. [view]
• Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 451(7177):425-30. [view]
• Virgen CA, Kratovac Z, Bieniasz PD, Hatziioannou T. 2008. Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc Natl Acad Sci. 105(9):3563-8.[view]
• Zhang F, Perez-Caballero D, Hatziioannou T, Bieniasz PD. 2008. No effect of endogenous TRIM5alpha on HIV-1 production. Nat Med. 14(3):235-6. [view]
• Kratovac Z, Virgen CA, Bibollet-Ruche F, Hahn BH, Bieniasz PD, Hatziioannou T. 2008. Primate lentivirus capsid sensitivity to TRIM5 proteins. J Virol. 82(13):6772-7. [view]
• Ho DD, Bieniasz PD. 2008. HIV-1 at 25.Cell. 133(4):561-5. [view]
• Jouvenet N, Bieniasz PD, Simon SM. 2008. Imaging the biogenesis of individual HIV-1 virions in live cells. Nature. 454(7201):236-40. [view]
• Lee YN, Malim MH, Bieniasz PD. 2008. Hypermutation of an ancient human retrovirus by APOBEC3G. J Virol. 2008 Sep;82(17):8762-70. [view]
• Perez-Caballero D, Soll SJ, Bieniasz PD. 2008. Evidence for restriction of ancient primate gammaretroviruses by APOBEC3 but not TRIM5alpha proteins. PLoS Pathog. 2008 Oct;4(10):e1000181. [view]
• Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, McNatt M, Hatziioannou T, Bieniasz PD. 2009. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol. 83(4):1837-44. [view]
• McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, Johnson WE, Neil SJ, Bieniasz PD. 2009. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 5(2):e1000300. [view]
• Hatziioannou T, Ambrose Z, Chung NP, Piatak M Jr, Yuan F, Trubey CM, Coalter V, Kiser R, Schneider D, Smedley J, Pung R, Gathuka M, Estes JD, Veazey RS, KewalRamani VN, Lifson JD, Bieniasz PD. 2009. A macaque model of HIV-1 infection. Proc Natl Acad Sci. 106(11):4425-9. [view]
• Brady T, Lee YN, Ronen K, Malani N, Berry CC, Bieniasz PD, Bushman FD. 2009. Integration target site selection by a resurrected human endogenous retrovirus. Genes Dev. 23(5):633-42. [view]
• Eastman SW, Yassaee M, Bieniasz PD. 2009. A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover. J Cell Biol. 184(6):881-94. [view]
• Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T. 2009. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe. 6(1):54-67. [view]
• Bieniasz PD. 2009. The cell biology of HIV-1 virion genesis. 5(6):550-8. Review. [view]
• Neil S, Bieniasz P. 2009. Human immunodeficiency virus, restriction factors, and interferon. 29(9):569-80. Review. [view]
• Jouvenet N, Simon SM, Bieniasz PD. 2009. Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. Proc Natl Acad Sci U S A. 106(45):19114-9. [view]
• Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell. 2009 Oct 30;139(3):499-511. [view]
• Sauter D, Schindler M, Specht A, Landford WN, Münch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn GH, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatziioannou, T, Kirchhoff F. 2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe. 6(5):409-21. [view]

* co-corresponding authors

---

Paul Bieniasz	Associate Professor, ADARC HOL, Rockefeller University
Mudathir Alim	Research Technician
Alaleh Ebrahimi	Research Technician
Nolwenn M. Jouvenet	Post Doctoral Fellow
Sebla Kutluay	Post Doctoral Fellow
Youngnam Lee	Graduate Student
Rachel Liberatore	Post Doctoral Fellow
Joseph Luna	Graduate Student
David Perez-Caballero	Research Scientist
Mathew McNatt	Post Doctoral Fellow
Steven Soll	Graduate Student
Constantin Takacs	Graduate Student
Sam J. Wilson	Post Doctoral Fellow
Shalini Yadav	Post Doctoral Fellow
Trinity Zang	Lab. Manager
Maria Zhandina	Graduate Student
FengWen Zhang	Post Doctoral Fellow